Opioid agonist/antagonist has a big impact in phase IIb trial ...

Learn to manage chronic fatigue from IPF with exercise, nutrition, sleep hygiene, and energy-saving strategies.

IPF-associated cough affects up to 80% of patients with IPF, substantially impairing their quality of life; consequently, ...

Environmental factors including temperature, humidity, air quality, and seasonal changes can significantly impact idiopathic pulmonary fibrosis (IPF). These triggers can exacerbate symptoms and lead ...

Among patients with idiopathic pulmonary fibrosis, the risk for all-cause mortality was significantly lower with vs. without ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with ...

Please provide your email address to receive an email when new articles are posted on . An online survey was created to capture the burden of IPF. Patients frequently reported shortness of breath. IPF ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...

1. Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to phase II clinical research in idiopathic pulmonary fibrosis. News release. Boehringer-Ingelheim. January 13, 2026. Accessed ...

Antifibrotic therapy shows similar efficacy in familial and sporadic IPF, with no significant differences in survival or acute exacerbations. Because familial idiopathic pulmonary fibrosis is ...

The MarketWatch News Department was not involved in the creation of this content. Ingelheim, Germany/Ridgefield, Connecticut, U.S. -- Idiopathic pulmonary fibrosis (IPF) is a progressive disease, ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...